HZNP News and Press, Horizon Therapeutics Public Limited Company From 02/11/22

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive. For further details see: Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named the Title Partner of the Irish Open in a six-year deal, which will begin with the 2022 Horizon Irish Open at Mount Juliet Estate in County Kilkenny, Ireland, from June 30 to July 3. This press release features...

A cluster of insider purchases at the utility NextEra Energy and the cable company Charter Communications. Four different insiders including both the CEO and CFO of NextEra Energy acquired shares after a rare large drop in the stock that saw it dip below the $70 level. Charter Com...

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2021 financial results on Tuesday, March 1, 2022. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company&#...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR 1 ) antagonist to treat people with IPF, the most common interstitial lung ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical stocks haven’t really had much since the pandemic hit. Most of the talk has been about the companies in a race for vaccines or treatments and the companies that are distributing vaccines and treatments...

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer Former oncology nurse and veteran pharmaceutical leader will oversee company's business operations PR Newswire LOS ANGELES , Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company foc...

-- Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients randomized to receive KRYSTEXXA plus methotrexate -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has submitted a supplemental Bi...

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. to be the first tenant at the Alexandria Center ® at Traville Gateway campus in Rockville, Maryland. When completed, the state-...

Halvorsen's 13F portfolio value increased from $32.98B to $36.04B this quarter. The number of positions increased from 88 to 96. Viking Global added McDonald’s and increased General Electric, Humana, Brookfield Asset Management, and Parker Hannifin while dropping Aon plc during...